计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L190223-250mg |
250mg |
现货 ![]() |
| |
| L190223-1g |
1g |
现货 ![]() |
| |
| L190223-5g |
5g |
现货 ![]() |
|
| 别名 | N-[5-[(4-乙基-1-哌嗪基)甲基]-2-吡啶基]-5-氟-4-[4-氟-2-甲基-1-异丙基-1H-苯并咪唑-6-基]-2-嘧啶胺 | 玻玛西林 | 阿贝西利 | ||||
|---|---|---|---|---|---|
| 英文别名 | L01XE50 | 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine | EX-A521 | LY 2835219 (free base) | NSC783671 | NSC-783671 | 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluor | ||||
| 规格或纯度 | Moligand™, ≥97% | ||||
| 英文名称 | Abemaciclib | ||||
| 储存温度 | 避光,-20°C储存 | ||||
| 运输条件 | 超低温冰袋运输 | ||||
| 作用类型 | 抑制剂 | ||||
| 作用机制 | 细胞周期蛋白依赖性激酶 6 抑制剂 | ||||
| 产品介绍 |
|
||||
| 纯度 | ≥97% | ||||
| ALogP | 3.8 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770692 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine |
| INCHI | 1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34) |
| InChi Key | UZWDCWONPYILKI-UHFFFAOYSA-N |
| Smiles | CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F |
| Isomeric SMILES | CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F |
| 分子量 | 506.59 |
| Reaxy-Rn | 20351282 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=20351282&ln= |
| 溶解性 | insoluble in H2O; ≥4.83 mg/mL in DMSO with gentle warming and ultrasonic; ≥6.34 mg/mL in EtOH with gentle warming |
|---|---|
| 敏感性 | 对光敏感 |
| 分子量 | 506.600 g/mol |
| XLogP3 | 3.800 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 9 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 506.272 Da |
| 单同位素质量Monoisotopic Mass | 506.272 Da |
| 拓扑极表面积Topological Polar Surface Area | 75.000 Ų |
| 重原子数Heavy Atom Count | 37 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 723.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS08 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H360: 可能损害生育力或未出生的孩子 H373: 通过长时间或反复暴露对器官造成损害 H410: 对水生生物有剧毒并具有长期持续影响 |
| 预防措施声明 |
P201: 使用前获取特殊说明 P202: 在阅读并理解所有安全预防措施之前,不要进行操作。 P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P314: 如果你感到不适,请就医。 P391: 收集溢出物 P308+P313: 如接触到或有疑虑:求医/就诊。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 |
| 1. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M et al.. (2010) The landscape of somatic copy-number alteration across human cancers.. Nature, 463 (7283): (899-905). [PMID:20164920] |
| 2. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M. (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.. Cancer Cell, 18 (1): (63-73). [PMID:20609353] |
| 3. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES. (2012) Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.. Cell Cycle, 11 (14): (2756-61). [PMID:22767154] |
| 4. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H et al.. (2012) The requirement for cyclin D function in tumor maintenance.. Cancer Cell, 22 (4): (438-51). [PMID:23079655] |
| 5. Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, Genesca L, Trimarchi T, Kelliher MA, Clark M et al.. (2012) Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.. Cancer Cell, 22 (4): (452-65). [PMID:23079656] |
| 6. Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH. (2013) A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.. Cancer Biol Ther, 14 (7): (597-605). [PMID:23792647] |
| 7. Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V et al.. (2016) Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.. Cancer Cell, 29 (3): (255-69). [PMID:26977878] |
| 8. Sun Chao-Yue, Talukder Milton, Cao Di, Chen Cun-Wu. (2022) Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells. Frontiers in Pharmacology, 13 [PMID:35814226] [10.3389/fphar.2022.829759] |
| 9. Xiao-yu Xu, Jing Chen, Zhong-xi Chen, Zhe-yan Zhang, Le-hao Jin, Jian-chao Luo, Yun-shan Zhong, Qi Zhou, Jian-chang Qian. (2025) CYP3A4 activity variations can lead to stratified metabolism of abemaciclib. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 304 (140836). [PMID:39933681] [10.1016/j.ijbiomac.2025.140836] |